Your session is about to expire
← Back to Search
Olaparib for Pancreatic Cancer
Study Summary
This trial is studying olaparib as a possible treatment for pancreatic acinar cell carcinoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken strong or moderate CYP3A inhibitors in the last 2 weeks.I have no severe side effects from past cancer treatments.I have recovered from recent surgeries and it's been over 2 weeks since any minor procedure.My kidneys are functioning well enough, based on a calculation involving my age, weight, and gender.I have been diagnosed with superior vena cava syndrome.I am 18 years old or older.I have symptoms of heart failure.My spinal cord compression is stable for 28 days after treatment.I agree to use birth control during the study because the medication may harm an unborn baby.I agree not to drink grapefruit juice during the study.I have unstable chest pain.I have had a bone marrow or cord blood transplant in the past.My kidney function, measured by creatinine clearance, is good.I have brain metastases that are not well-controlled without increasing medication.I have no cancer other than PACC, or any I had was cured over 5 years ago, except for certain skin, cervical, breast, or endometrial cancers.I do not have any serious uncontrolled illnesses besides cancer.My hemoglobin level is at least 10 g/dL without recent blood transfusions.I had a heart attack in the last 3 months.I have been diagnosed with myelodysplastic syndrome or acute myeloid leukemia.I can provide my past medical records.It has been over 3 weeks since my last chemotherapy or radiation therapy.My organ and bone marrow functions are within normal ranges.My lung scan shows widespread scarring or inflammation.You have had allergic reactions to drugs that are similar to olaparib.I cannot take pills by mouth or have a stomach condition that affects medication absorption.I am breastfeeding and do not want to stop.I have a lot of fluid in my abdomen, low blood protein, or had fluid removed recently.My pancreatic cancer diagnosis has been confirmed by NIH pathology.It's been over 5 weeks since I last used specific strong medications.I have had one chemotherapy treatment or cannot have it, and my tumor cannot be surgically removed.I am fully active and can carry on all my pre-disease activities without restriction.I have frequent and uncontrolled seizures.
- Group 1: Arm 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many subjects are involved in this experiment?
"Affirmative. According to clinicaltrials.gov, the trial that was initially posted on December 6th 2022 is still looking for participants and has been edited as recently as November 30th 2022. 20 people need to be recruited at a single site."
Has the FDA given its stamp of approval to Olaparib?
"Olaparib's safety is rated a 2 on the scale due to only preliminary data being available that suggests its security; there has yet to be any evidence indicating efficacy."
Are there any openings to participate in this experiment as a subject?
"The information located on clinicaltrials.gov suggests that this medical trial is currently enrolling volunteers; the first listing of which was posted December 6th 2022, with a subsequent update made at the end of November 2022."
Share this study with friends
Copy Link
Messenger